UN chief appoints new Special Envoy in move to end Tuberculosis

Dr. Eric Goosby, the new UN Special Envoy on Tuberculosis, will work towards boosting the profile of the fight against TB and promoting the adoption, financing and implementation of the UN WHO’s global End TB Strategy after 2015.

Read More →

Drug-resistant tuberculosis a tiny — but potent — foe in L.A. County

Otsuka rejected Dr. Caitlin Reed’s attempt to obtain delamanid for her patient, Gary, who has the most drug-resistant case of TB ever identified in the United States.

Read More →

Presenting the new and improved TBOnline.info – your source for TB news!

We are pleased to announce the completed renovation of TB Online – a website for activists, patients, healthcare workers, and researchers to learn more about tuberculosis (TB).

Read More →

Aidspan releases new analysis of TB drug pricing trends

The analysis illustrates important differences in costs of anti-TB medications and highlights potential areas of intervention for initiatives aimed at accelerating progress towards achieving global TB targets, through increasing access to affordable anti-TB medications.

Read More →

Lives at stake in Eastern Ukraine

Concerns are growing over the disruption in treatment for people living with HIV and tuberculosis in Eastern Ukraine where fighting in the rebel-controlled territories of Donetsk and Luhansk has interrupted crucial medical supplies.

Read More →

"Reach, Treat, Cure Everyone": Stop TB Partnership announces theme for World TB Day 2015

For World TB Day 2015, partners will continue to call for a global effort to find, treat and cure all people with TB and accelerate progress towards the bold goal of ending TB by 2035.

Read More →

Real engagement with communities

The affected communities should no longer be passive recipients of care but valuable partners with decision-making power in choices and policies that affect them.

Read More →

Latent TB: Shorter course of therapy effective in children

In children with latent tuberculosis, 3 months of combined therapy with isoniazid and rifapentine is safe and as effective as 9 months of isoniazid alone.

Read More →

Activism on rifapentine pricing: removing cost barriers to improve the uptake of tuberculosis research innovations

The article details the advocacy campaign that led Sanofi to decrease the price of TB drug rifapentine by 57% in the United States.

Read More →

CRAG: A Protocol Review Companion for Activists

The document is designed to facilitate community reviews of clinical trials protocols and to ensure community participation in protocol development.

Read More →

Page 1 of 50 · Total posts: 10

1 2 Last→